Eli Lilly and Company (NYSE:LLY) Trading Up 1.9% – Time to Buy?

Shares of Eli Lilly and Company (NYSE:LLY) shot up 1.9% during mid-day trading on Wednesday . The company traded as high as $1,093.00 and last traded at $1,085.3570. 2,535,932 shares traded hands during trading, a decline of 20% from the average session volume of 3,179,649 shares. The stock had previously closed at $1,064.74.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Health restored broader coverage for Lilly’s obesity treatments Zepbound and Foundayo, a major commercial win that could expand access for millions of U.S. patients and strengthen Lilly’s position against Novo Nordisk. CVS brings back coverage for Lilly’s obesity drug Zepbound
• Positive Sentiment: Lilly’s stock hit record highs after the CVS coverage news, reinforcing the view that improved pharmacy-benefit-manager access is a key catalyst for revenue growth in its obesity franchise. LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
• Positive Sentiment: Lilly reported positive Phase 1b results for Verve-102, adding to optimism around its pipeline beyond obesity and diabetes. Eli Lilly (LLY) Reports Positive Phase 1b Verve-102 Study Results
• Positive Sentiment: The company’s planned acquisition of Curevo Vaccine and other vaccine developers signals a meaningful new growth avenue and shows Lilly is deploying capital aggressively outside its core obesity business. Eli Lilly to acquire Bothell’s Curevo Vaccine for $1.5 billion
• Neutral Sentiment: Wall Street closed higher broadly, with healthcare stocks participating, which may be providing a favorable backdrop for Lilly’s move. Stock Market News for May 29, 2026
• Neutral Sentiment: Management also continues to highlight pipeline progress, including new data presentations at upcoming diabetes and obesity conferences, which supports the long-term story but is less immediate than the CVS access win. Lilly to present new data on Foundayo, Mounjaro and retatrutide
• Negative Sentiment: Some commentary suggests Lilly’s valuation is already rich, and comparisons with Novo Nordisk continue to raise questions about how much upside is left after the recent run. Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. Rothschild & Co Redburn raised their price target on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Finally, Guggenheim reaffirmed a “buy” rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market cap of $1.04 trillion, a price-to-earnings ratio of 39.24, a price-to-earnings-growth ratio of 1.18 and a beta of 0.48. The company has a fifty day moving average price of $952.15 and a two-hundred day moving average price of $1,009.10.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LLY. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $25,000. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $30,000. Miller Global Investments LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $33,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after acquiring an additional 24 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.